Seroxat (Paxil/Aropax) is one of the most controversial drugs of the past 20 years:
Birth defects, severe withdrawal symptoms, suicide, self harm, addiction, dependence, extreme debilitating side effects, controversy, lawsuits, headlines, fraud, corrupt sales practices, corrupt doctors and psychiatrists, documentaries, you tube videos, blogs, books, websites, users groups, internet forums….
Seroxat has it all…
Yet, GSK still makes £435 million a year on sales of this nasty drug.
You would have to ask? Are those whom remain on Seroxat too addicted to come off it…
Is this profiting from addiction?..
GSK’s cardiovascular and urogenital franchise generated 2011 turnover of £2.47 billion, a year-on-year rise of 8%. Within this, benign prostatic hyperplasia drug Avodart (dutasteride) sales reached £748 million, a leap of 20%, but blood thinner Arixtra (fondaparinux) declined 7% to £276 million. The central nervous system franchise was down 2% to £1.72 billion for the year, With Keppra (levetiracetam) contributing £53 million, up 20%, and Lamictal (lamotrigine) for seizures and bipolar disorder adding 536 million, a rise of 8%, while the antidepressant Seroxat/Paxil (paroxetine) generated £435 million sales, a fall of 13%. Oncology and emesis product contributed £693 million sales, up 2%, with breast cancer drug Tyverb/Tykerb (lapatinib) rising by the same percentage to £231 million.